Catalogo dei prodotti della ricerca

GELIBTER, ALAIN JONATHAN
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.664
EU - Europa 1.427
AS - Asia 689
AF - Africa 44
SA - Sud America 12
OC - Oceania 2
Totale 4.838
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.628
IT - Italia 856
SG - Singapore 291
SE - Svezia 254
IN - India 188
CN - Cina 112
DE - Germania 75
FI - Finlandia 52
ID - Indonesia 42
CA - Canada 32
EG - Egitto 30
BG - Bulgaria 28
IE - Irlanda 25
RO - Romania 23
FR - Francia 20
GB - Regno Unito 19
ES - Italia 18
KR - Corea 16
HK - Hong Kong 15
UA - Ucraina 15
NL - Olanda 14
TG - Togo 14
TR - Turchia 8
AR - Argentina 6
IR - Iran 5
BE - Belgio 4
GR - Grecia 4
MX - Messico 4
CZ - Repubblica Ceca 3
DK - Danimarca 3
AU - Australia 2
BR - Brasile 2
CH - Svizzera 2
CO - Colombia 2
JO - Giordania 2
LT - Lituania 2
MY - Malesia 2
PK - Pakistan 2
PT - Portogallo 2
SI - Slovenia 2
AT - Austria 1
CL - Cile 1
EC - Ecuador 1
IL - Israele 1
KG - Kirghizistan 1
KH - Cambogia 1
KZ - Kazakistan 1
MK - Macedonia 1
NO - Norvegia 1
PH - Filippine 1
PL - Polonia 1
RS - Serbia 1
RU - Federazione Russa 1
UZ - Uzbekistan 1
Totale 4.838
Salva come PNG Salva come JPEG
Città #
Fairfield 427
Rome 298
Ashburn 243
Chandler 216
Seattle 200
Singapore 193
Woodbridge 176
Wilmington 151
Cambridge 150
Houston 148
Princeton 77
San Paolo di Civitate 73
Santa Clara 65
Beijing 61
Lawrence 53
Milan 53
New York 46
San Diego 46
Helsinki 41
Jakarta 41
Millbury 34
Ann Arbor 31
Damanhur 29
Sofia 28
Boston 26
Dublin 25
Dearborn 23
Bremen 17
Boardman 16
Plano 16
Andover 15
Falls Church 15
Perugia 15
Toronto 15
Lomé 14
Washington 14
Florence 12
Hong Kong 12
Turin 12
Naples 11
Norwalk 11
Madrid 9
Ottawa 9
Genoa 8
Istanbul 8
Los Angeles 8
Salt Lake City 8
Barcelona 7
Leawood 7
Mannheim 7
Pomezia 7
Bühl 6
Des Moines 6
Federal 6
Hyderabad 6
Cassano Allo Ionio 5
London 5
Phoenix 5
Sacramento 5
San Mateo 5
Segrate 5
Albano Laziale 4
Amsterdam 4
Birmingham 4
Brussels 4
Catania 4
Dallas 4
Fremont 4
Goyang-si 4
Imperia 4
Kunming 4
Lappeenranta 4
Mantova 4
Messina 4
New Delhi 4
Paris 4
Venice 4
Bengaluru 3
Buffalo 3
Changsha 3
Chiesina Uzzanese 3
Dongjak-gu 3
Ferentino 3
Glasgow 3
Grafing 3
Hangzhou 3
Hefei 3
Imola 3
Mexico City 3
Montreal 3
Montréal 3
Nanjing 3
Padova 3
Pesaro 3
Rizziconi 3
Shanghai 3
Stockholm 3
Tolfa 3
Amman 2
Arezzo 2
Totale 3.412
Salva come PNG Salva come JPEG
Nome #
Circulating CD137 + T cells correlate with improved response to anti-PD1 immunotherapy in cancer patients 153
TK inhibitor pazopanib primes DCs by downregulation of the β-catenin pathway 152
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study 106
Burned-out testicular cancer: really a different history? 105
Transient disappearance of RAS mutant clones in plasma: A counterintuitive clinical use of EGFR inhibitors in RAS mutant metastatic colorectal cancer 104
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 99
The agnostic role of site of metastasis in predicting outcomes in cancer patients treated with immunotherapy 89
Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors. an important role for mutations in minor clones 88
Coexistence of three EGFR mutations in an NSCLC patient: A brief report 85
Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers 84
Adjuvant chemotherapy in resected colon cancer: when, how and how long? 81
PD-L1 and epithelial-mesenchymal transition in circulating tumor cells from non-small cell lung cancer patients: a molecular shield to evade immune system? 80
Italian Nivolumab Expanded Access Program in Nonsquamous Non-Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients 80
Circulating Cancer-Associated Macrophage-like Cells as a Blood-Based Biomarker of Response to Immune Checkpoint Inhibitors 78
EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapy 77
Fixed-dose-rate gemcitabine. A viable first-line treatment option for advanced pancreatic and biliary tract cancer 77
Response to immunotherapy in KRAS G12C mutated NSCLC: a single-centre retrospective observational study 77
First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer 74
Molecular and genetic bases of pancreatic cancer 73
Aromatase inhibitors in post-menopausal metastatic breast carcinoma 72
New approaches to prevent intestinal toxicity of irinotecan-based regimens 71
Exploratory pilot study of circulating biomarkers in metastatic renal cell carcinoma 71
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: When overweight becomes favorable 71
Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment. A meta-analysis 70
The role of opioids in cancer response to immunotherapy 70
Emerging pathways and future targets for the molecular therapy of pancreatic cancer 66
Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease 63
Advances towards the design and development of personalized non-small-cell lung cancer drug therapy 63
Are dose-finding studies still necessary when targeted therapy is associated with chemotherapy? [5] 63
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index 63
127P {RAS}, {RAF} and {NF}1 oncogenic mutations in {KRAS}-mutated lung adenocarcinoma 62
Bevacizumab: One treatment for all the seasons? [5] 62
Immune-related adverse events of pembrolizumab in a large real-world cohort of patients with NSCLC with a PD-L1 expression ≥ 50% and their relationship with clinical outcomes 62
KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden 62
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence 62
CD137+ and regulatory T cells as independent prognostic factors of survival in advanced non-oncogene addicted NSCLC patients treated with immunotherapy as first-line 61
Thyroid disorders in programmed death 1 inhibitor-treated patients: Is previous therapy with tyrosine kinase inhibitors a predisposing factor? 59
Circulating CD137+T cells as an immune biomarker for response to anti-PD1 immunotherapy in NSCLC patients 58
Old age: Biologic versus chronologic [15] 57
Efficacy and tolerability of selective internal radiotherapy with Yttrium-90 as consolidation treatment after chemotherapy in metastatic colorectal cancer 57
Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation by Braaten et al: another point of view 56
Comparison of two blood-based genotyping tests to investigate the KRAS G12C mutation in patients with non-small-cell lung cancer at failure of first-line treatments 56
null 54
Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes 53
Intensified total neoadjuvant therapy in patients with locally advanced rectal cancer: a phase II trial 53
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors. the multicenter FAMI-L1 study 50
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50% 50
null 50
null 49
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation 49
Changing monoclonal antibody keeping unaltered the chemotherapy regimen in metastatic colorectal cancer patients: Is efficacy maintained? 48
Status of correlation between BMI and response to immunocheck-point inhibitor in advanced non-small-cell lung cancer 48
3MO Oncogenic non-G12C {KRAS} mutations in {KRAS} G12C mutated lung adenocarcinomas in {TRACERx} and {GENIE}: A reservoir for intrinsic resistance to {KRAS} G12C inhibitors 48
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%. A multicenter study with external validation 47
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice 47
Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: A pooled analysis of the randomised trials 46
Smoking status during first-line immunotherapy and chemotherapy in NSCLC patients: a case-control matched analysis from a large multicenter study 46
Evaluation of drug-drug interactions in EGFR-mutated non-small-cell lung cancer patients during treatment with tyrosine-kinase inhibitors 46
null 42
Immunomodulatory effects of tyrosine kinase inhibitors (TKIs) in renal cell carcinoma (RCC) patients 42
Effect of bone metastases on immunotherapy efficacy in pretreated advanced non small cell lung cancer (NSCLC). 41
Impact of sarcopenia and inflammation on patients with advanced non-small cell lung cancer (Ncscl) treated with immune checkpoint inhibitors (icis): a prospective study 40
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort 40
Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer 39
CA 72-4, CA 19-9 and CEA in monitoring adjuvant and metastatic colorectal cancer 39
ALK Traslocated Pulmonary Sarcomatoid Carcinoma 38
Sequential chemotherapy in nonsmall-cell lung cancer: Cisplatin and gemcitabine followed by docetaxel 37
Metastatic renal cell carcinoma management: from molecular mechanism to clinical practice 37
null 36
null 36
Comparative effects of Folfirinox and Gemcitabine/nab-paclitaxel as first and second line chemotherapy for metastatic pancreatic cancer: single choice or sequence 36
CA 242 in colo-rectal and pancreatic cancer 34
Gemcitabine-based combinations for inoperable pancreatic cancer: Have we made real progress? A meta-analysis of 20 phase 3 trials 34
Women with synchronous or metachronous lung and ovarian cancer: A multi-institutional report 34
Treg/CD137+ T cell balance as a novel biomarker of survival in advanced non-addicted NSCLC patients treated with immunotherapy as first-line 33
Malignant bronchial Abrikossoff's tumor and small cell lung cancer: A case report and review 33
Circulating CD137+ T cell subsets and MDCSs as immune biomarkers for response to anti-PD1 immunotherapy in NSCLC patients 31
Renal function outcomes in metastatic non-small-cell lung carcinoma patients treated with chemotherapy or immune checkpoint inhibitors: an unexpected scenario 31
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status 29
Surgical and survival outcomes with perioperative or neoadjuvant immune-checkpoint inhibitors combined with platinum-based chemotherapy in resectable NSCLC: A systematic review and meta-analysis of randomised clinical trials 28
COMPARISON OF CEA, MCA, CA 15-3, CA 27-29 IN FOLLOW UP AND MONITORING THERAPEUTIC RESPONSE IN BREAT CANCER PATIENTS 28
Evaluation of efficacy of ALK inhibitors according to body mass index in ALK rearranged NSCLC patients—A retrospective observational study 28
Safety and efficacy of combining afatinib and whole-brain radiation therapy in treating brain metastases from EGFR-mutated NSCLC: a case report and literature review 25
Circulating natural killer cells as prognostic value for non-small-cell lung cancer patients treated with Immune checkpoint inhibitors: correlation with sarcopenia 24
Rheumatic Diseases Development in Patients Treated by Anti-PD1 Immune Checkpoint Inhibitors: A Single-Centre Descriptive Study 22
Co-Occurrence of ALK rearrangement and KRAS G12C mutation in NSCLC: Report of two cases 21
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer 21
966P Diabetes therapy burden as proxy of impairment of immune checkpoint inhibitors efficacy 20
Use of adjuvant chemotherapy after surgery in patients with colon cancer 19
EP08.02-046 Activity of OsimeRTInib in NSCLC with Uncommon EGFR Mutations: Retrospective Observational Multicenter Study (ARTICUNO) 17
null 17
null 17
10P Family history of cancer correlates with improved outcome from immunotherapy in NSCLC independent of somatic DNA damage response gene status 16
Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy 15
Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients 15
Prolactin as a Potential Early Predictive Factor in Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab 15
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy 14
[Immunotherapy in non-small cell lung cancer patients: back to the future.] 13
Testicular ultrasonographic features predict future risk for bilateral testicular germ cell tumour: A long-term single centre follow-up study 12
Use of nivolumab in elderly patients with advanced squamous non–small-cell lung cancer: results from the Italian cohort of an expanded access programme 11
Totale 5.163
Salva come PNG Salva come JPEG
Categoria #
all - tutte 18.949
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.949
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020839 0 0 0 0 69 83 177 163 138 117 72 20
2020/2021577 55 32 34 32 10 16 26 45 53 92 84 98
2021/2022878 24 24 48 47 150 47 49 91 65 55 169 109
2022/20231.052 186 228 92 92 99 78 22 92 66 32 46 19
2023/2024963 50 85 34 59 106 193 33 91 11 121 94 86
2024/2025585 81 86 129 161 128 0 0 0 0 0 0 0
Totale 5.199